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The current controversy surrounding the introduction of the French abortifa-
cient, RU 486, into the U.S. should not be simplistically characterized as the
FDA~s failure to admit a promising new drug for women. Rather, the furious
debate over this drug derives from an entire systemic failure { a failure to take
responsibility. A failure by the medical and scientic community to fully and ob-
jectively assess the known and unknown dangers to woments health and safety.
A failure by purveyors of information in the manipulation of theoretical and
highly preliminary evidence regarding potential uses for this drug in the treat-
ment of several tragic diseases. A failure of the Food and Drug Agency itself to
make clear both to itself and to the public its policies, and its justications for
its policies. A failure of Congress to providing leadership and guidance from a
democratic majority on this issue which aects our entire country. And, most
of all, a failure of the American public to truthfully scrutinize the Ichoicesl#
we are making for ourselves and to take responsibility for their implications and
consequences. Many of us would rather place the burden on deciding the cor-
rect course of action solely on the manufacturer of the drug. RU486 is merely
another tool which may be used to bring life or death, suering or its alleviation
in the hands of men and women. In order to decide how to use that tool wisely,
or to abstain from using it all, we must look closely at facts and the nature
of what is at stake, and each of us take responsibility for arriving at reasoned
solutions.
L The FDA must scrutinize the safety and ecacy claims of RU486 as the
rst step in assessing its
use as an abortifacient within the U.S.
In order to market a new drug in the U.S., a manufacturer must rst demon-
strate that the drug is eective and safe for its intended use. Foreign clinical
trials may be acceptable for this purpose, as long as the data generated meet
the same standards as studies performed in the U.S. Part of the FDAs oversight
involves the minimization of bias in the testing of a new drug. Therefore, man-
ufacturers are generally expected to utilize independent medical experts to test
their compounds, thereby ensuring objectivity and neutrality in the generation
and analysis of study data.
The synthetic drug. RU-486 (mifepristone) was developed in 1982 by French
scientist Dr. Etienne-Emile Baulieu, consultant to Roussel Uclaf (a subsidiary
of the parent German company, Hoechst AG). The drug moved quickly into
clinical trials in women, after only 17 months of animal research. Early clinical
trials included small
1numbers of women, ranging from 35 to 271 women, and took place in Geneva,
France, Sweden, Australia, Holland, the U.S., England, Finland and China.
However, the largest studies supporting its use in Europe were conducted by
Roussel Uclaf or by entities aliated with the French company. (Klein at 12,
1991) In 1988, when Roussel decided to suspend distribution of RU 486, the
French government, which owns 36% of Roussel Uclaf, ordered the company to
place the drug back on the market. The justication given for its order was
that RU 486 was the moral property of women, while making no reference to
its safety or ecacy. (Nau and Nouchi, 1988)
The reported success rates of RU486 (if of women in administration 486 re-
sulted in complete termination of pregnancy without the need for surgical inter-
vention) was found to be between 60 (Herrmann, 1982) and 70% (Kovacs, 1984).
In order to improve the drug's success rate, RU 486 began to be administered
in combination with another class of compounds known as prostaglandins
(PGs), which induce uterine contractions, thereby facilitating the expulsion of
the embryo from the body. The addition of a prostaglandin, such as misopristol
(Cytotec) and gemeprost, improved the success rate to above 90%, and remains
the current practice. However the addition of this second powerful class of com-
pounds has raised important considerations regarding the safety of this drug
combination.
It is often true, that the more powerful a drug in achieving its desired pur-
poses, the greater its potential for producing undesired outcomes. In considering
the safety risk of a new drug, the FDA must consider the action of the drug
upon the body (more specically, the manner in which the drug is absorbed,
distributed in body tissue, metabolized and excreted) and the inuence of other
chemicals on its action when taken in combination. Moreover, what is not known
may be just as important as what is known about a drug in an assessment of its
safety. The perceived desirability of a new drug should not be allowed to under-
cut in way close and objective scrutiny of the complications, adverse events and
contraindications and signicant unanswered questions, as this is an essential
pert of the critical judgment the agency must make in weighing the risks and
benets of a drug's use in the U. S.
The action of RU 486 and its interaction with PG is complex and far from
fully understood. RU 486 is theorized to induce abortion by blocking the action
of the hormone, progesterone, in the uterus which is needed to maintain preg-
nancy. Progesterone is a steroid hormone with diverse eects in the reproductive
system, the breasts and the central nervous system. Because of its ability to
bind to the progesterone receptor, RU 486 may have untold eects beyond the
uterus, given that is taken systemically. RU 486 is also a glucocorticoid blocker,
in which case it would also aect the adrenal glands. Increased susceptibility to
infection is a common result of adrenal
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2insuciency, raising the question of whether the drug's antiglucocorticoid eect
may implicate a woman's recovery in the event of the need for curettage after
a failed RU 486-induced abortion. Because no sophisticated pharmacokinetic
studies have been done, the drug's half-life of RU 486 also remains undened,
in which case the question of how long its systemic eects may last remains un-
known. Furthermore, because no adequate dose response studies appear to have
been conducted (generally done in the second phase of American trials), nei-
ther is the optimal dosing or therapeutic ratio as yet known. Rather, arbitrary
doses have been selected which achieve results eective in inducing abortion;
however, what does appear certain at this point is that the current 600 mg dose
is in excess of what is actually required. (JoM, 196)
While the addition of POs clearly improve the ecacy of RU 486, they also
contribute signicantly to concerns for side-eects. PGs are a class of highly
active hormone-like compounds whose understood limits of safe usage is still in
its infancy. They have marked cardiovascular actions and are theorized to be
the major cause of the cardiovascular events and other major noxious side eects
experienced with the combined RU48 6/PG treatment. Immune suppression is
a common ethical compromise made in patients treated with PGs for cancer
and tissue transplant. To date, however, no known studies have been done
researching the potential of RU486 and PG. taken in combination, to weaken
the immune defense against malignancy and infection, nor any other of the
potential adverse short or long-term eects resulting from their interaction.
Furthermore, within the U.S., no prostaglandin has been approved for abortion
purposes, raising separate safety, labeling and marketing issues for the use of
this combination within the U.S., should NDAs be submitted.
Signicant adverse reactions and complications have been experienced in
studies performed with the RU486/PG combination. Published reports all speak
of pain, severe cramping. nausea, vomiting. and bleeding among study partic-
ipants. Incomplete abortions may occur between 2% (Gao, 1988) and 13%
(Rodger and Baird, 1989), which requires a woman to undergo surgical abor-
tion in order to avoid infection. Severe and prolonged bleeding. lasting from one
to 44 days (mean duration 8-10 days) is reported, with some women requiring
transfusions and curettage. (idJ) Pain is also the common experience with this
procedure; the drug's manufacturer in the U.K.. has acknowledged that 30% of
the women required narcotics for their pain. (Roussel Laboratories, 1991).
RU 486/PG has caused one death, in 1989, and a number of serious car-
diovascular side eects, two of which where life-threatening. (New York Times,
1991) After having reviewed the data of 30,000 women, ap international group
of scientists and doctors in Paris urged the Ministry of Health to immediately
suppress the distribution and
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3use of RU 486 because of the grave secondary eects of chemical abortion which
is falsely seen as an alternative to surgical abortion. (Kami, at 9, 1990) As a re-
sult of these events, the company circulated to all clinics strict guidelines, adding
asthma, cardiovascular risk facts, e.g. smoking, obesity, elevated serum lipids,
diabetes and high blood pressure to the list of contraindications, and excluding
women over the age of 35. (Le Quotidien De Medicin, 1990). Women with
a number of other potential contraindications have been excluded from clinical
studies. These include menstrual irregularities (Couzninet, 1986); women with
broids or endometriosis (Li, 1988); cervical incompetence (Grimes, 1988) and
previous abortion history (Grimes, 1990); use of oral contraceptives within three
months of conception (Swahn and Bygdeman, 1989). Therefore, unknown po-
tential for injury to women exists by RU 486 if they have an undetected medical
condition, or because such women with these medical histories have not been
adequately represented in the testing of this drug.
A nal consideration for the safe use of RU 486 is the regimen of drugs which
is used to accomplish chemical abortion, refereed to by some as the Chemical
Cocktail. (Klein at 486, 1991) As noted above, RU 486 must be taken with a PG
in order to achieve acceptable levels of ecacy. Added to this is the common
use of narcotics and other analgesics for the pain experienced by women during
this process. Furthermore, antibiotics for potential infection due to incomplete
abortions, oral contraceptives to stop bleeding. and anti-diarrhea and anti-
nausea medications for gastro-intestinal side-eects are often given to women.
Potential adverse drug interactions for these mixtures, however, have not been
closely studied.
Because of legitimate safety concerns, chemical abortions induced by the
RU 486/PG combination are currently given under strict medical supervision
in Europe. The French government, the manufacturer, and physicians adminis-
tering the drug regimen throughout Europe consistently arm that to maintain
safety, extremely close medical supervisor is required. This concern for women's
safety is echoed as well here in U.S. where the American Medical Association
has asserted that RU 486 poses a severe risk to patients unless administered as
part of a complete treatment plan under the supervision of a physical (testi-
mony of Dr. P. John Seward of the American Medical Association before the
U.S. House of Rep. Subcommittee on Regulation, Business Opportunities, and
Energy, Nov. 9, 1990). A woman wishing to utilize this method must make
a total of four visits to an authorized clinic or hospital equipped with an elec-
trocardiogram, cardiorespirator and coronary spasm medication. (Muhi at 321,
1993) On the rst visit, a woman discusses this option with a physician and
submits to a physical examination which includes a pelvic exam a pregnancy
test, and possibly a vaginal ultrasonogram to determine if she is within the
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442 day window in which she may take the drug. A woman must then return
to the clinic or hospital after at least a 24 hour waiting period, at which time
she takes the RU 486 in the presence of a nurse or doctor. On the third visit,
two days later, the woman is administered PG either by injection or by vaginal
suppository. She must lie prone and have her blood pressure checked on a regular
basis. Expulsion of the embryo may occur while at the clinic, however, many
women must wait days to weeks before her body voids the embryo. Therefore,
the woman must return a fourth time for a physical examination to make sure
abortion is complete. If not, conventional abortion must be performed..
II. Manipulation and mischaracterization of facts concerning the use
and benets of RU 486 to gain public support for its entry into the U.S.
Probably the most compelling claim made on behalf of RU 486 is that it
will make the obtaining of an abortion a more private and convenient event.
However, it is clear that obtaining a chemical abortion by the use of the RU
486/ PG drug regimen is neither simple nor private. Rather it is a complicated,
multi-step process involving pain, heavy bleeding, and other noxious side-eects.
Neither will it relieve a woman of invasive medical treatment, given the numer-
ous examinations and tests to which she must submit. Nor will it increase her
opportunity for autonomy and self-control in the midst of her abortion. Rather,
it will increase the decree of medical intervention and control over her by in-
creasing the amount of visits she must make to a health facility, the number of
medications she must take (and her exposure to nsks of adverse drug interac-
tions), and the length of time she must be monitored and treated for a successful
abortion.
In assessing the desirability of RU 486 as an alternative to the current form
of abortion, the drug regimen should be compared directly to currently used
forms of abortion. Although a claimed advantage of RU486 is that it avoids
the risks of surgery and anesthesia, in fact, surgery and general anesthetic is
not administered with many conventional abortions (i.e., vacuum aspiration in
which a local is given). Conventional abortions are 99% percent eective, require
1-2 medical visits, have fewer contraindications and complications, and can be
performed over a wider range of time post-conception. (Klein at 50, 1991) It
has been acknowledged by Edouard Sakiz~ chairman of Roussel Uclaf, that, As
abortifacient procedures go, RU 486 is not at all easy to use. In fact it is much
more complex than the technique of vacuum extraction. True, no anesthetic is
required. But a woman who wants to end her pregnancy has to 'live with' her
abortion for at least a week using this tenique. It's an appalling psychological
ordeal. (Boston Herald, Jul. 31, 1992) Attesting to the reality of this statement
is a study published last year in
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5France which showed that among women who had received the RU 486/PG
combination regimen, three times as many were unsatised with this regimen
as with curettage oered under either local or general anesthesia (Institute of
Medicine at 184, 1993)
Because of the chemical nature of RU 486, as both a chemical blocker of sex
hormones and glucocorticoids, has understandably lead the scientic community
to hypothesize about potential uses of this drug as a research and therapeutic
tool in areas other than abortion. However, in order to accurately assess the
known benets of this drug it is necessary to look closely at the evidence un-
derpinning claims of eectiveness for the treatment of other conditions. In their
zeal to appeal to their respective audiences, the media, and certain sectors of
the medical and political community have acted irresponsibly in holding out RU
486 as more than medical science knows it to be. This has the aect of playing
to people's hopes and perhaps desperate situations, while failing to form a solid
foundation for rationale and well-balanced decisions regarding the use of this
drug.
Claims for uses other than abortion include (most notably) pre and post-
coital oral contraception, menses regulation, cervical dilation, endometriosis,
breast cancer, meningioma and Cushings Disease. However, at present, these
claims are preliminary at best in that they are based only upon theoretical pro-
jections, sparse animal data and small, uncontrolled clinical studies. None have
been suciently promising for the company to seek licenses for any indication
other than abortion (the only indication for which signicant evidence of ecacy
or safety has been generated).
As a morning after pill or menstrual regulator, RU 486 is not generally con-
sidered because it causes a womans ovulatory and menstrual cycles to become
unlinked. Furthermore, the relative value of RU 486 for contraception cannot
even be judged until the long-term eects of continuous administration is known,
which is clearly not known.
Several studies in animals showed that RU486 have raised interest for the
use of this compound in controlling estrogen-dependent conditions such as en-
dometriosis and breast cancer, however, A very limited body of data shows
mixed and unclear results. A study in monkeys reveals that higher doses of the
antiprogestin both elevates the concentration and deactivates the estrogen re-
ceptor (Hodgen, 1991), and in rats, no regression of endometriosis was observed
when treated with RU 486. (Tjaden, 1993) A study in six women found no
signicant change in the extent of the disease when treated for 3 months, while
longer treatment (6 months) in 9 women showed signicant improvement in 8
of 9 women. (unpublished observation by Samuel Yen at Univ. of Cal.).
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6Despite hopes to the contrary, the clinical activity of antiprogestins, such as RU
486, in breast cancer patients is, in reality sparse and clinically unimpressive.
Data on only 11 post-menopausal patients treated with RU 486 have been pub-
lished, in which regression was reported in no patients, while delayed toxicity~s
(weight loss, fatigue, anorexia, nausea, malaise, somnolence and one grand mal
seizure) were experienced. (Michna, 1992). Further complicating the picture
is a study conducted last year in the University of Wisconsin Cancer Center,
which found that RU 486 actually stimulated the growth of human breast cancer
cells in vitro at a concentration found in women taking RU 486. (Jeng, 1993)
Therefore, RU 486 appears to have both estrogen inhibitory and stimulatory
activity which may call into question its use as a treatment for estrogen-driven
breast cancer.
Only two small studies have been performed with RU486 in the treatment of
meningiomas (rare inoperable brain tumors). The rst involved 14 patients for
periods ranging from 2 to 31 months, in which 5 patients showed reduced tumor
measurement, with relatively mild side-eects. (Grunberg, 1991) In the second,
of 10 patients receiving RU 486, control of tumor growth was seen in six patients,
while progression of tumor growth occurred in four patients. (Lamberts, 1992)
While encouraging, the clinical importance of these observations in patients
having a disease with a highly variable natural history clearly remains to be
dened. [see endnotes for brief discussion of Cushing's Disease]
III. The Development of a National Policy regarding RU
486 - the Responsibility of the FDA and Congress.
A. The FDA Import Alert of 1988 banning RU 486 from Importation
for Personal Use.
In light of the safety issues and unanswered questions highlighted above, the
FDA had sound scientic basis for concluding RU486 represents a signicant
health risk, and thus banning its import for personal use. The FDA has more
to think about than one isolated woman who may bring the drug into the country
under the best of circumstances. In developing its import alert policy, the FDA
must envision the risks engendered in the drug's average expected use and weigh
this against the benets hoped to be achieved by permitting its importation.
A strict and fairly elaborate medical protocol is strictly required for its safe
and eective use in Europe. Many questions critical to the health and well-
being of women remain unanswered regarding RU 486, such as its full impact
on the reproductive systems and other organ systems, its long-term eects on
a woman's subsequent fertility, and the dangers involved in its concomitant use
with other medications, to mention a few. RU 486 carries with it an extensive
list of contraindications for conditions relatively common and often undiagnosed
and untreated within the
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7U.S. female population, due to lack inadequate health care or simple ignorance.
None of the PG's used in combination with RU 486 is approved in this country
for abortion. Further complicating the medical considerations are the societal
issues. The danger of the current atmosphere of political and ideological postur-
ing is that the misperceptions and mischaracterizations propagated regarding
the drug are more likely to contribute to its misuse, thereby increasing the risks
of its use. Given the fact that once in the country, the FDA retains little ability
to regulate and safeguard its use, the agency is left with little choice but to ban
its import for all but research purposes.
In weighing the risks and benets of permitting the entry of RU 486 for per-
sonal use, the FDA must bear in mind all its intended uses. The most common
reason for importing RU 486 is likely to be for terminating pregnancy, a use
for which a safe and eective method already exists in this country. However,
demand for RU 486 also exists for deadly diseases treatable only a few drastic
means, most notably breast cancer and a rare form of brain tumor (menin-
giomas). Here, again, a reasoned assessment of the facts is critical to the proper
development of FDA policy. As noted above, the scientic data simply does
not support, as yet, the conclusion that RU 486 is a viable cure for breast
cancer; and one in vitro study raises questions as to whether it may stimulate
the growth of cancer cells. While the medical case for meningiomas is a bit
stronger, further clinical study is clearly needed before any rm conclusions can
be drawn. A further consideration is whether by permitting the importation of
RU 486 for these experimental personal uses, patients forego other treatments,
such as surgery or chemotherapy, for the promise of a more convenient cure',
thereby allowing their medical status to worsen. What the FDA must ask itself
is whether the strength of the scientic data, in terms of potential benets to
cancer (and other) patients, outweighs the risks posed by the use of RU 486 for
the purposes it is likely to be imported. Given the known and unknown dangers,
when taken alone, or with PG for abortion, as well as the weakness of the scien-
tic date for its proposed benets in other indications, the FDA was reasonable
in considering the importation RU 486 for personal use to pose an unreasonable
risk to the public. However, rather than blindly maintain a policy in the face
of evolving medical insight, the FDA should consider specic exemptions from
its general import alert when scientic and medical data justify doing so, as,
potentially, in the case of treating inoperable meningiomas.
Where the FDA has most notably failed in its policy, however, is in that it
promulgated rules having important public consequences without conducted an
investigation into the medical and ethical considerations and without explicitly
communiating the justications for its policy. Neither has it provided opportu-
nity for public comment either before or since the promulgation of its import
rule. Regardless of whether the agency had authority
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8articulated judgment call, explicitly stating the reasons and justications for
the agency's actions, pursuant to investigative proceedings giving opportunity
for comment from the public. This approach would have facilitated the ow
of information needed to dispelled many of misperceptions regarding RU 486
currently held by the public, and would have maintained the agency's legiti-
macy in reaching a controversial policy decision, even ~f it was the wrong
in its decision (strangely enough Americans seem to have more respect for
a potentially wrong decision made openly and explicitly, than for a potentially
right decision made in a questionable manner). However, instead the agency
relied on letters to senators and testimony in Senate hearings to clarify its po-
sition. This has created the appearance of the agency as merely covering up a
purely politically-motivated decision post hoc, and has permitted the political
and ideological grandstanding. and public misperceptions to continue to under-
mine rationale consideration of the issues surrounding the introduction of this
drug. An administrative agency comes closest to illegitimacy when it acts in
non-compliance with its own rules and fails spell out clearly what it is doing;
and by doing so fails to take full responsibility for its important and controver-
sial judgments. The FDA may not have purposefully set out to do this, but by
acting in the manner in which, it accomplished as much.
Soon after entering the oval oce, President Clinton instructed the FDA to
revoke its exclusion of RU 486 if sucient evidence does not exist warranting
its continued exclusion. Essentially, the FDA has being called upon to do what
it should have done in the rst place, to make itself accountable for its decisions
which have intimately aected people. However, in meeting's the President's
challenge to its current policy, the FDA must do two things. It must make
a careful and objectively assessment the scientic and medical data regarding
the risks and benets of importing this drug. as well as the implications of
the current misleading claims regarding its use. Tn doing so it should resist
political inuence to suppress valid concerns regarding its safety (by the left
wing) or to exclude the drug for scientically and ethically sound uses (by the
right wing). Secondly, the agency must establish for itself a fundamental policy
regarding the ethical implications of the use of RU 486, which it has thus far
been able to escape doing no NDAs have been submitted its approval in this
country. Only by doing these things will it ultimately be able to preserve its
autonomy. legitimacy and the public faith it has striven so hard to maintain.
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9B. Developing a sound medical and ethical policy regarding the poten-
tial approval of RU 486
Until recently, Hoechst AG has been extremely reluctant to permit its sub-
sidiary, Roussel Uclaf to make available RU 486 in the U.S. In 1992, Roussel
Uclaf issued several required conditions before marketing the drug for abor-
tion in any country.1 Frequent allegations have been levied that FDA hostility
towards the drug (as evidenced by its placement on import alert) is responsi-
ble for the company's unwillingness to pursue clinical testing and marketing of
RU 486 within the U.S. However, numerous statements by the company belie
the common assumption that political pressure or the FDA Import Alert has
determined their decision. Rather, they cite their own internal policies and
standards regarding study protocols, and the conditions explicitly laid down for
their agreeing to commence clinical testing. Less frequently mentioned, how-
ever, is chairman Wolfgang Hilger's moral conviction that Hoechst should not
market RU 486 and that commercialization of a drug facilitating abortion is
against Hoechst's corporate credo. (Wall St. Journal, Feb 22, 1993) It is rea-
sonable to assume that the company's desire to avoid boycotts, tort liability and
political hassle play some role in the its reluctance to enter into the American
market. However, respect for the private decision making of a company oper-
ating in the U.S. must be maintained. This is particularly true where moral
convictions regarding the ethical use of its products combines with rational eco-
nomic self-interest (although, it may be argued that moral convictions may have
actually overshadowed economic considerations in Hoechst~s decision, given the
enormous prot which could have been made in this country). The American
system of medical innovation is based in large part upon private initiative in
research and development, in that the FD&C Act explicitly places responsibil-
ity for testing new drugs on the manufacturer who desires FDA approval. The
FDA has no authority to require a company to investigate a new drug. however
promising, nor can any citizen compel the FDA to undertake studies of a drug
or to permit a drug to be made available for treatment. See, e.g., DeVito v.
HEM, Inc., 705 F.Supp. 1076 (MiD. Pa 1988) While the FDA should encourage
applications for compassionate ThJDs for persons with these other indications
who cannot be satisfactorily treated by available alternative methods, attempt-
ing to compel the licensing of RU 486 in the U.S. by its manufacturer, while
lacking statutory mandate or authority to do so, would be an illegitimate use
and expansion of the FDA's power.
Inevitably, however, at some point the future, the FDA will receive an ap-
plication for RU486, or some other similar compound. The FDA will then have
to face squarely the fundamental ethical issue of whether to permit the
i(l) Abortion is legal and accepted by society, as demonstrated by a statutoly
ruling on abortion. (2) The availability of PF and strictly controlled distribution
and use of RU 486 would mimic that of France. (3) A representative, competent
body makes written request for the drug.
10
10marketing of this drug in this country, and the regulatory issues which would
follow, such as its labeling and distribution. One may approach this from two
perspectives. The rst concludes that the agency will have camed out its ethi-
cal duty to society by strictly scrutinizing the available date and mandating the
full barrage of clinical trials necessary to establish its long as well as short-term
safety and ecacy of the drug. Under this standard, the European data is not
likely to answer all the agency's misgivings with regards to its use in abortion
(given what is currently known), if the it conducts its duty with scientic purity
and integrity. If it has learned anything from its experience with oral contracep-
tives and IUDs, where the long-term health risks to women should have been
assessed prior to their approval, the agency will move forward with this latest
reproductive drug very cautiously, and let politics be damned.
With regards to its approval for other uses for RU 486, the FDA should
require the complete animal and clinical testing for each indication, given that
the state of the scientic and medical data is clearly highly preliminary. Because
of its potential for use in certain life threatening conditions, the review process
should be expedited, but only to the extend that safety and ecacy is not
compromised. However, at the point in which an Investigational New Drug
applications may be sought, the FDA should allow the use of compassionate (or
treatment) INDs for concomitant treatment of patients with serious diseases,
for which RU 486 shows real promise, and for which no alternative treatments
are available.
The second approach, however, calls for a more controversial ethical judg-
ment. It postlates that the FDA possesses the discretion to decide on an ethical
basis that certain goals are morally inappropriate for the U.S. government to
permit or to pursue. An example of such a judgment, is the FDA policy pro-
hibiting U.S. companies from distributing abroad drugs not approved in this
country, but which the receiving country would nd uriobjectionable by their
own standards of safety and ecacy. hi this situation, the FDA is essentially
saying that we, the U.S. government, are not going to permit you, a sovereign
nation, to have a drug which you desire, but which feel may harm you. You may
obtain the treatment through some other means, as we cannot control all your
available choices. However, as a matter of ethical principle, we, as a government,
will not permit ourselves to be the means by which you exercise your right of
choice to your own potential detriment (realizing that the issue of detriment
itself is also a judgment call). Similarly, it is my contention that the FDA has
the right to refuse to act in a manner desired and legally permitted of others in
the interest of protecting the potential life of the unborn. In reality, this is the
central rationale of the FDA's refusal to approve the marketing of Thalidomide,
even with proper labeling. The FDA made a ethical judgment that in
11
11order to safeguard the life and health of the unborn, it was worth giving up the
benets potentially derived by the use of that drug.
The refusal to permit the marketing of drugs for abortion may appear to
some a radical idea, but truly it is not in light of the FDA's mandat6 to protect
life and health, rather than to assist in extinguishing it. The fact that the life
it would protect is at such an early stage in its development when terminated
does not change the analysis, because it is still life regardless of the labels that
may be placed upon it. Roe and Casey make clear that the government may
not armatively act to burden the abortion decision, for which current forms
of abortion remain constitutionally protected for the present. However, neither
case imposes a duty upon the government to assist in facilitating the termination
of life. As noted in Webster, the government has the right to safeguard potential
life by all constitutionally permissible means. I would like to suggest, however
unpopular the suggestion, that the refusal by the FDA to approve RU 486 for
the purposed of achieving chemical abortion in this country, is one of those
means, fully justied by the undeniable safety hazards posed by this drug to
the smallest members of our society.
It may then be asked, however, if the FDA is able to make such a value
judgment to restrict the availability of a safe and eective drug in this setting.
upon what principle may we be reassured that it will not do so in other settings,
with possibly disagreeable results from the other point of view. Where ends the
capricious discretion of the agency? The answer to this question is two-fold.
Firstly, the issue of abortion is indeed unique (diering even from that of assisted
suicide) in that it involves not just the wishes and safety of one individual, the
mother, but also that of a second individual, the unborn child, who cannot give
consent to the harm perpetrated against it. I would pose that this is where the
FDA's mandate is most compelling. to ensure and protect the health and safety
of the most vulnerable members of our society who will inevitably be harmed
if the agency fails to take action. Secondly, the FDA is always accountable,
ultimately, to a democratic majority of the public through Congress. If indeed
it has acted so far aeld of the collective conscience of our people by denying
approval to this drug. it is realistically possible for our feelings to triumph over
FDA policy should the consensus be strong.
In reality, given the current political climate I would expect that a decision
by the FDA to disapprove RU 486 for abortion purposes would be likely be over-
turned by Congress. However, because this process would potentially achieve
several important ends, I do not think it would be pointless or meaningless.
Firstly, it will permit the FDA to carry out its essential mandate, that of pro-
tecting the public health and safety, with respect to the most vulnerable of our
society, the unborn. Secondly, it will require Congress to shoulder its rightful
duty in providing guidance to both the
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12agency and to the American public with respect to this extremely dicult and
contentious moral and ethical issue, rather than simply permitting a few out-
spoken congresspersons and powerful interest groups (the medical community
included), to control the nature and outcome of the debate. Lastly, by highlight-
ing the true nature of this drug, the FDA would hopefully cause the American
public to stop and realistic assess the true nature of our choices and to realize
that with choice comes responsibility and the consequences of that freedom,
which brings me to my nal and most important point.
The question we must ask ourselves, in considering the proper outcome to
this debate, and many others currently like it, is whether, in reality, greater
technology truly is always represents progress. Or rather, has technology in
cases such as these merely allowed us to abdicated our responsibilities for our
poor choices, so that in turn we place unrealistic, and almost desperate demands
upon technology, and the entities who produce it, to provide us only short-term
and inferior solutions to our problems. The critical lesson to learned of RU 486
is that quick xes are an illusion; they are no substitute for each of us coming
fully to terms with the real consequences of in our decisions, behavior, and social
interactions. Our poor self-discipline, thoughtlessness, and lack of basic human
dignity, leave us wanting easy, painless and private solutions, while attempting
to ameliorate, deny or absolve ourselves of the burdens accompanying our rights.
This, in my mind, is what RU 486 is essentially about. Will this drug truly
empower people to choose, or will it merely enable people to helplessly react;
because, in truth, who would choose to undergo the physical and emotional
ordeal of several trips to the hospital, to have someone peer and probe the
intimate parts of your body and to cause you pain, bleeding and discomfort by
giving you a powerful, and still rather mysterious chemical, so that you may
ush yourself of a part of your being you wished your had never conceived in
the rst place.
What role the FDA should play in the development of an increasingly drug-
driven society is at the crux of its current dilemma, for which I do not have the
answers. My greater purpose in posing the above options and questions is not to
provide detailed solutions, which would probably just distract the reader from
the greater search for the acceptable answers. Rather, my real goal in writing
this paper is to sharpen the reader's focus on the cold facts and realities, so
that we as a society, and the FDA as an agency with a great deal of sway and
discretion, may begin to grapple with the true nature of our choices; and thus
that we may begin to exercise our precious nght of choice wisely.
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13ENDNOTES
(1) Cushing's Disease: RU 486 has been used to treat Cushings Disease
in one study by Bertagna. who state that this compound should not be consid-
ered a routine alternative for the treatment of Cushing's Disease. (Bertagna,
1986)
As imilar report by Nieman concluded that it shows some eectiveness,
but is not proven safe. (Nieman, 1985) According to Roussel Uclaf, RU 486
shows ecacy only in two very rare form of Cushing's syndrome, which is
itself a very rare disease. (Letter to Dr. E.H. Drew, Jan. 19, 1992)
(2) Personal Note: As a woman, I do not lack compassion and in-
sight into the enormous personal and ethical burden involved in the abortion
decision, and the issues surrounding the legal right to obtain one. Neither do I
think that
acting in any way which seems to restrict this right is politically expedient.
However, I argue this position as a matter of conviction, which in many ways
is not unlike the basic judgment that Congress and the FDA must make on a
regular
basis.
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